The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

We recently published Jim Cramer's Biggest Winners to Buy: Top 20 AI & Other Stocks He Got Right in 2026. Johnson & Johnson (NYSE:JNJ) is one of the stocks discussed by Jim Cramer.

Healthcare giant Johnson & Johnson (NYSE:JNJ)'s shares are up by 68% over the past year and by 26% year-to-date. The firm reported its fourth quarter earnings on January 21st. It posted $24.56 billion in revenue and $2.46 in earnings per share to beat analyst estimates. Crucially, Johnson & Johnson (NYSE:JNJ) also forecast full year revenue to range between $99.5 billion and $100.5 billion and full year profit per share to sit between $11.43 to $11.63 to beat analyst estimates for both metrics. Cramer has been increasingly optimistic about Johnson & Johnson (NYSE:JNJ) for nearly a year now. Some factors that have caught his attention include a robust oncology portfolio and overall business streamlining. On April 14th, Johnson & Johnson (NYSE:JNJ)'s first quarter earnings saw it post $24.1 billion in revenue and $2.70 in adjusted earnings to beat analyst estimates. It also raised its full year guidance again. Here is what Cramer said about the firm in January:

Trong Nguyen / Shutterstock.com

"The fastest grower, the best opportunity here would not be Eli Lilly, which has moved a great deal and I still like, but Johnson & Johnson. It's spinning off its orthopedics business, DePuy Synthes, something that will immediately raise its price-to-earnings multiple because that business has much slower growth than the core pharma franchise. Same thing happened when J&J spun off Kenvue, its over-the-counter drug business. Great move to raise the valuation. At one point, this stock was down more than $5 today. I think it's a terrific entry point even down three."

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.